SAGIMET BIOSCIENCES INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.33 USD | +1.17% |
|
+5.35% | -20.11% |
| 06/05 | Sagimet Biosciences Names Thierry Chauche CFO | MT |
| 06/05 | Sagimet Biosciences Inc. Announces Appointment of Thierry Chauche as Chief Financial Officer | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 142M 11.82B |
|---|---|---|---|---|---|
| Net income 2024 * | -59M -4.92B | Net income 2025 * | -115M -9.59B | EV / Sales 2024 * | - |
| Net cash position 2024 * | 142M 11.87B | Net cash position 2025 * | 217M 18.1B | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-2.04
x | P/E ratio 2025 * |
-1.12
x | Employees | 9 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.59% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.17% | ||
| 1 week | +5.35% | ||
| Current month | +11.03% | ||
| 1 month | -19.52% | ||
| 3 months | -27.83% | ||
| 6 months | +23.36% | ||
| Current year | -20.11% |
1 week
4.04
4.76
1 month
3.835.30
Current year
3.8320.71
1 year
2.1320.71
3 years
2.1320.71
5 years
2.1320.71
10 years
2.1320.71
| Managers | Title | Age | Since |
|---|---|---|---|
David Happel
CEO | Chief Executive Officer | 62 | 24/22/24 |
George Kemble
CHM | Chairman | 63 | 15/11/15 |
Elizabeth Rozek
CMP | Compliance Officer | 53 | 01/23/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Beth Seidenberg
BRD | Director/Board Member | 67 | 01/07/01 |
Richard Rodgers
BRD | Director/Board Member | 57 | 01/15/01 |
| Director/Board Member | 60 | 01/21/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 0 M€ | +3.45% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/24/08 | 4.44 | +2.54% | 312,710 |
| 07/24/07 | 4.33 | +1.17% | 288,054 |
| 06/24/06 | 4.28 | -0.93% | 559,222 |
| 03/24/03 | 4.32 | -2.92% | 770,647 |
| 02/24/02 | 4.45 | +8.27% | 1,127,748 |
End-of-day quote Nasdaq, May 07, 2024
More quotes
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and the selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). In addition to MASH, the Company is evaluating denifanstat in acne and in select forms of cancer, disease areas in which dysregulation of fatty acid metabolism also plays a key role. Denifanstat is being tested in a Phase III clinical trial for moderate to severe acne vulgaris, and a Phase III trial for recurrent glioblastoma multiforme (GBM) in combination with bevacizumab.
Calendar
05/06/2024
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.44
USD
Average target price
40
USD
Spread / Average Target
+800.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.11% | 138M | |
| +22.56% | 46.4B | |
| -1.51% | 41.75B | |
| +48.83% | 41.37B | |
| -3.42% | 29.71B | |
| +10.13% | 26.01B | |
| -20.44% | 19.52B | |
| +26.45% | 12.43B | |
| -0.14% | 12.18B | |
| -0.47% | 12.13B |
- Stock Market
- Equities
- SGMT Stock